Ablation of Cytochrome P450 Omega-hydroxylase 4A14 Gene Attenuates Hepatic Steatosis and Fibrosis

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2017 Mar 9

PMID 28270609

Citations 56

Authors

Xiaoyan Zhang

Sha Li

Yunfeng Zhou

Wen Su

Xiongzhong Ruan

Bing Wang

Feng Zheng

Margaret Warner

Jan-Ake Gustafsson

Youfei Guan

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is characterized by simple hepatic steatosis (SS), nonalcoholic steatohepatitis (NASH), hepatic fibrosis, and cirrhosis. Dysregulated fatty acid metabolism in the liver plays a critical role in the pathogenesis of NAFLD. Cytochrome P450 omega-hydroxylase 4A14 (CYP4A14) is a homolog of human CYP4A hydroxylase that catalyzes omega-hydroxylation of medium-chain fatty acids and arachidonic acid in mice. The goal of this study was to determine the role of CYP4A14 in the development and the progression of NAFLD. Here, we showed that hepatic CYP4A expression was up-regulated in the livers of patients and three murine models of NAFLD. Adenovirus-mediated overexpression of CYP4A14 in the livers of C57BL/6 mice resulted in a fatty liver phenotype with a significant increase in hepatic fatty acid translocase (FAT/CD36) expression. In contrast, CYP4A14 gene-deficient mice fed a high-fat diet or a methionine and choline-deficient (MCD) diet exhibited attenuated liver lipid accumulation and reduced hepatic FAT/CD36 expression. In addition, hepatic inflammation and fibrosis was markedly ameliorated in MCD diet-fed CYP4A14-deficient mice. Collectively, CYP4A14 plays an important role in the pathogenesis of both SS and NASH and may represent a potential therapeutic target for the treatment of NAFLD.

Citing Articles

Dose-Dependent PFESA-BP2 Exposure Increases Risk of Liver Toxicity and Hepatocellular Carcinoma.

Kostecki G, Chuang K, Buxton A, Dakshanamurthy S Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996819 PMC: 11854358. DOI: 10.3390/cimb47020098.

The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.

Hardwick J, Song B, Rote P, Leahy C, Lee Y, Wolf A Front Physiol. 2025; 15:1497297.

PMID: 39959811 PMC: 11826315. DOI: 10.3389/fphys.2024.1497297.

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma.

Alpizar Salazar M, Olguin Reyes S, Medina Estevez A, Saturno Lobos J, De Aldecoa Castillo J, Carrera Aguas J Medicina (Kaunas). 2025; 61(1).

PMID: 39859069 PMC: 11766802. DOI: 10.3390/medicina61010088.

Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease.

Lee M, Son M, Hong S, Ryu J, Min J, Lee D Clin Transl Med. 2024; 14(10):e1816.

PMID: 39367660 PMC: 11452733. DOI: 10.1002/ctm2.1816.

Elongation factor 1A1 inhibition elicits changes in lipid droplet size, the bulk transcriptome, and cell type-associated gene expression in MASLD mouse liver.

Wilson R, Chen Y, Zhang R, Maini S, Andrews T, Wang R Am J Physiol Gastrointest Liver Physiol. 2024; 327(4):G608-G622.

PMID: 39136056 PMC: 11482270. DOI: 10.1152/ajpgi.00276.2023.

References

Su W, Wang Y, Jia X, Wu W, Li L, Tian X . Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2014; 111(31):11437-42. PMC: 4128098. DOI: 10.1073/pnas.1410741111. View

Wang C, Chen Z, Li S, Zhang Y, Jia S, Li J . Hepatic overexpression of ATP synthase β subunit activates PI3K/Akt pathway to ameliorate hyperglycemia of diabetic mice. Diabetes. 2013; 63(3):947-59. DOI: 10.2337/db13-1096. View

Miquilena-Colina M, Lima-Cabello E, Sanchez-Campos S, Garcia-Mediavilla M, Fernandez-Bermejo M, Lozano-Rodriguez T . Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 2011; 60(10):1394-402. DOI: 10.1136/gut.2010.222844. View

Patsouris D, Reddy J, Muller M, Kersten S . Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology. 2005; 147(3):1508-16. DOI: 10.1210/en.2005-1132. View

Gyamfi M, Tanaka Y, He L, Klaassen C, Wan Y . Hepatic effects of a methionine-choline-deficient diet in hepatocyte RXRalpha-null mice. Toxicol Appl Pharmacol. 2008; 234(2):166-78. PMC: 2656443. DOI: 10.1016/j.taap.2008.09.022. View

Weltman M, Farrell G, Liddle C . Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 1996; 111(6):1645-53. DOI: 10.1016/s0016-5085(96)70028-8. View

Clark J, Brancati F, Diehl A . Nonalcoholic fatty liver disease. Gastroenterology. 2002; 122(6):1649-57. DOI: 10.1053/gast.2002.33573. View

Chatuphonprasert W, Nemoto N, Sakuma T, Jarukamjorn K . Modulations of cytochrome P450 expression in diabetic mice by berberine. Chem Biol Interact. 2012; 196(1-2):23-9. DOI: 10.1016/j.cbi.2012.01.006. View

Mishra A, Younossi Z . Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2015; 2(2):135-44. PMC: 3940561. DOI: 10.1016/S0973-6883(12)60102-9. View

10.

Silverstein R, Febbraio M . CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009; 2(72):re3. PMC: 2811062. DOI: 10.1126/scisignal.272re3. View

11.

Holla V, Adas F, Imig J, Zhao X, Price Jr E, Olsen N . Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci U S A. 2001; 98(9):5211-6. PMC: 33189. DOI: 10.1073/pnas.081627898. View

12.

Simpson A . The cytochrome P450 4 (CYP4) family. Gen Pharmacol. 1997; 28(3):351-9. DOI: 10.1016/s0306-3623(96)00246-7. View

13.

Robertson G, Leclercq I, Farrell G . Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001; 281(5):G1135-9. DOI: 10.1152/ajpgi.2001.281.5.G1135. View

14.

Enriquez A, Leclercq I, Farrell G, Robertson G . Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun. 1999; 255(2):300-6. DOI: 10.1006/bbrc.1999.0202. View

15.

Martin C, Chevrot M, Poirier H, Passilly-Degrace P, Niot I, Besnard P . CD36 as a lipid sensor. Physiol Behav. 2011; 105(1):36-42. DOI: 10.1016/j.physbeh.2011.02.029. View

16.

Park E, Kim S, Hong Y, Hwang J, Cho G, Cha H . Inhibition of CYP4A reduces hepatic endoplasmic reticulum stress and features of diabetes in mice. Gastroenterology. 2014; 147(4):860-9. DOI: 10.1053/j.gastro.2014.06.039. View

17.

Wang C, Chi Y, Li J, Miao Y, Li S, Su W . FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis. Hepatology. 2014; 59(5):1779-90. DOI: 10.1002/hep.26945. View

18.

Zhang Y, Yeager R, Tanaka Y, Klaassen C . Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. Toxicol Appl Pharmacol. 2010; 245(3):326-34. PMC: 3180859. DOI: 10.1016/j.taap.2010.03.016. View

19.

Zhang Y, Klaassen C . Hormonal regulation of Cyp4a isoforms in mouse liver and kidney. Xenobiotica. 2013; 43(12):1055-63. PMC: 4091904. DOI: 10.3109/00498254.2013.797622. View

20.

Gyamfi M, Damjanov I, French S, Wan Y . The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem Pharmacol. 2007; 75(4):981-95. PMC: 2323588. DOI: 10.1016/j.bcp.2007.09.030. View